SWEDISH ORPHAN/S (OTCMKTS:SWTUY) and INDUSTRIA DE DI/ADR (OTCMKTS:IDEXY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.
This table compares SWEDISH ORPHAN/S and INDUSTRIA DE DI/ADR’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|INDUSTRIA DE DI/ADR||13.32%||26.06%||14.47%|
This is a breakdown of recent ratings and recommmendations for SWEDISH ORPHAN/S and INDUSTRIA DE DI/ADR, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|INDUSTRIA DE DI/ADR||0||1||0||0||2.00|
INDUSTRIA DE DI/ADR pays an annual dividend of $0.35 per share and has a dividend yield of 2.2%. SWEDISH ORPHAN/S does not pay a dividend. INDUSTRIA DE DI/ADR pays out 53.8% of its earnings in the form of a dividend.
Insider and Institutional Ownership
0.0% of INDUSTRIA DE DI/ADR shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
SWEDISH ORPHAN/S has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, INDUSTRIA DE DI/ADR has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
Valuation and Earnings
This table compares SWEDISH ORPHAN/S and INDUSTRIA DE DI/ADR’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SWEDISH ORPHAN/S||$763.19 million||0.00||$134.73 million||$0.50||N/A|
|INDUSTRIA DE DI/ADR||$30.72 billion||3.21||$4.04 billion||$0.65||24.36|
INDUSTRIA DE DI/ADR has higher revenue and earnings than SWEDISH ORPHAN/S. SWEDISH ORPHAN/S is trading at a lower price-to-earnings ratio than INDUSTRIA DE DI/ADR, indicating that it is currently the more affordable of the two stocks.
SWEDISH ORPHAN/S beats INDUSTRIA DE DI/ADR on 8 of the 13 factors compared between the two stocks.
SWEDISH ORPHAN/S Company Profile
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
INDUSTRIA DE DI/ADR Company Profile
Industria de Diseño Textil, S.A. engages in the retail and online distribution of clothing, footwear, accessories, and household textile products through various commercial concepts. Its retail concepts include Zara, Pull & Bear, Massimo Dutti, Bershka, Stradivarius, Oysho, Zara Home, and Uterqüe. The company operates 7,490 physical stores in 96 markets; and online stores in 156 markets. It is also involved in textile manufacturing, design, financial services, real estate, logistic, insurance, and combined heat and power plant, and construction businesses. The company operates in Spain, rest of Europe, the Americas, Asia, and internationally. Industria de Diseño Textil, S.A. was founded in 1963 and is based in A Coruña, Spain.
Receive News & Ratings for SWEDISH ORPHAN/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SWEDISH ORPHAN/S and related companies with MarketBeat.com's FREE daily email newsletter.